Mills Stephen J., Potter Barry V. L.
Department of Medicinal Chemistry, School of Pharmacy and Pharmacology, University of Bath, Claverton Down, Bath, BA2 7AY, UK.
J Org Chem. 1996 Dec 13;61(25):8980-8987. doi: 10.1021/jo961280x.
A regioisomer of the second messenger D-myo-inositol 1,4,5-trisphosphate [D-Ins(1,4,5)P(3), 1], DL-myo-inositol 1,4,6-trisphosphate [DL-Ins(1,4,6)P(3), 4ab], together with the chiral antipodes D-Ins(1,4,6)P(3)(4a) and L-Ins(1,4,6)P(3)(4b), was synthesized from myo-inositol. The racemic diol 6, after removal of the trans-ketal of fully protected 5 was p-methoxybenzylated to give the 6-O-alkylated derivative 9, as the major product in 52% yield. Gentle acidic hydrolysis of 9, followed by benzylation of the resulting triol, gave the fully protected compound 11ab. Isomerization of the two allyl groups followed by acidic hydrolysis of the resulting cis-prop-1-enyl moieties and the p-methoxybenzyl group gave the triol 13ab. Phosphorylation of 13ab followed by deprotection of the resulting compound, 14ab, with sodium in liquid ammonia and purification by ion exchange chromatography provided 4ab in 60% yield. The intermediate 9 was converted into the cis-diol 16ab in two steps. Selective acylation at the equatorial hydroxyl group using (S)-(+)-O-acetylmandelic acid in the presence of DCC and DMAP provided two diastereoisomers, 18 and 19, which were separated by flash chromatography. Further transformations provided the corresponding D- and L-1,4,6 triols, 13a and 13b, respectively, and phosphorylation, followed by deprotection of the fully blocked products as for the racemic 4ab, gave 4a and 4b, respectively. The absolute configuration of fully protected 11a was determined by transformation to the known compound L-1,2,4,5-tetra-O-benzyl-myo-inositol (22). Compound 4a was a full agonist at the platelet Ins(1,4,5)P(3) receptor for Ca(2+) release, but 4b was devoid of activity.
第二信使D-肌醇1,4,5-三磷酸[D-Ins(1,4,5)P₃, 1]的一种区域异构体,DL-肌醇1,4,6-三磷酸[DL-Ins(1,4,6)P₃, 4ab],连同手性对映体D-Ins(1,4,6)P₃(4a)和L-Ins(1,4,6)P₃(4b),由肌醇合成。外消旋二醇6在去除完全保护的5的反式缩酮后,进行对甲氧基苄基化反应,得到6-O-烷基化衍生物9,产率为52%,为主要产物。对9进行温和的酸水解,然后对所得三醇进行苄基化反应,得到完全保护的化合物11ab。两个烯丙基异构化,随后对所得顺式丙-1-烯基部分和对甲氧基苄基进行酸水解,得到三醇13ab。对13ab进行磷酸化反应,然后用液氨中的钠对所得化合物14ab进行脱保护,并通过离子交换色谱法纯化,得到4ab,产率为60%。中间体9分两步转化为顺式二醇16ab。在DCC和DMAP存在下,使用(S)-(+)-O-乙酰扁桃酸对赤道羟基进行选择性酰化,得到两种非对映异构体18和19,通过快速色谱法分离。进一步的转化分别得到相应的D-和L-1,4,6-三醇13a和13b,磷酸化后,按照外消旋体4ab的方法对完全封闭的产物进行脱保护,分别得到4a和4b。完全保护的11a的绝对构型通过转化为已知化合物L-1,2,4,5-四-O-苄基-肌醇(22)来确定。化合物4a是血小板Ins(1,4,5)P₃受体上Ca²⁺释放的完全激动剂,但4b没有活性。